Surely you agree that for some people, 42x would be the preferred method of treatment though? The global market for OSA is $10b per year. If IHL takes even 1% of that we are talking $100m USD annual revenue. You don't think that's perceivable?
- Forums
- ASX - By Stock
- IHL
- Ann: IHL-42X phase 2 clinical trial presentation
Ann: IHL-42X phase 2 clinical trial presentation, page-38
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)